Indigenous and Improved Bacterially Fermented CBD, CBG and Related Cannabinoid Oral Dosage Forms
The present invention is a cannabidiol (CBD), cannabigerol (CBG) or related cannabinoid oral dosage form including bacterially fermented hemp, typically compounded as a tablet or formulated within a capsule or as an additive to other dietary supplements or functional foods. The dosage forms contain dietary fiber, important to activity as the desired delivery system, having a ratio of one part soluble dietary fiber to 30 parts insoluble dietary fiber, which is an optimal fiber ratio for oral delivery and bioavailability of cannabidiol, cannabigerol and other desirable cannabinoids from either activated or native hemp.
1 . A cannabinoid oral dosage form in unit dosage form, consisting essentially of bacterially fermented hemp, compounded as a tablet or within a capsule, powder or other unit dosage form, having a soluble dietary fiber to insoluble dietary fiber ratio of 1:30, having a maximum cannabinoid dose per unit dosage form of 25 mg, and having viable bacteria therein as a probiotic dietary supplement.
2 . The cannabinoid oral dosage form according to claim 1 , wherein said bacterially fermented hemp contains cannabinoid acids in chemically stabilized form.
3 . A cannabinoid oral dosage form in unit dosage form, consisting essentially of bacterially fermented hemp, compounded as a tablet or within a capsule, powder or other unit dosage form as the predominant or exclusive ingredient and having increased cannabinoid in the amount of 12-300 percent compared to the starting hemp material prior to bacterial fermentation.
4 . The oral dosage form of claim 1 , wherein each oral dosage form contains less than 10% water as moisture and wherein said cannabinoid is one or more of cannabidiol, cannabigerol, cannabidivarin, cannabichromene, or cannabinol.
5 . The oral dosage form of claim 1 , wherein said hemp is fermented with one or more bacteria selected from the group consisting of Bacillus subtilis, Bacillus subtilis ssp Natto, Bacillus coagulans, Lactobacillus plantarum, Acetobacter pasteurianus, Acetobacter ghanensis, Komagataeibacter oboediens , and Komagataeibacter saccharivorans prior to compounding.
6 . The oral dosage form of claim 1 , wherein said dosage form contains no more than 10 mg cannabinoid per unit dosage form.